- Home
- MREO vs CADL Comparison
MREO vs CADL Comparison
Compare MREO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- CADL
- Stock Information
- Founded
- MREO 2015
- CADL 1999
- Country
- MREO United Kingdom
- CADL United States
- Employees
- MREO N/A
- CADL N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- MREO Health Care
- CADL Health Care
- Exchange
- MREO Nasdaq
- CADL Nasdaq
- Market Cap
- MREO 281.6M
- CADL 313.5M
- IPO Year
- MREO N/A
- CADL 2021
- Fundamental
- Price
- MREO $1.79
- CADL $5.10
- Analyst Decision
- MREO Strong Buy
- CADL Strong Buy
- Analyst Count
- MREO 5
- CADL 5
- Target Price
- MREO $7.40
- CADL $19.80
- AVG Volume (30 Days)
- MREO 1.2M
- CADL 716.6K
- Earning Date
- MREO 08-12-2025
- CADL 08-14-2025
- Dividend Yield
- MREO N/A
- CADL N/A
- EPS Growth
- MREO N/A
- CADL N/A
- EPS
- MREO N/A
- CADL N/A
- Revenue
- MREO $500,000.00
- CADL N/A
- Revenue This Year
- MREO N/A
- CADL N/A
- Revenue Next Year
- MREO $55.50
- CADL N/A
- P/E Ratio
- MREO N/A
- CADL N/A
- Revenue Growth
- MREO N/A
- CADL N/A
- 52 Week Low
- MREO $1.47
- CADL $3.79
- 52 Week High
- MREO $4.72
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- MREO 52.86
- CADL 36.62
- Support Level
- MREO $1.68
- CADL $5.70
- Resistance Level
- MREO $1.83
- CADL $6.04
- Average True Range (ATR)
- MREO 0.08
- CADL 0.32
- MACD
- MREO 0.03
- CADL -0.10
- Stochastic Oscillator
- MREO 82.61
- CADL 20.07
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.